openPR Logo
Press release

Achondroplasia Market on Track for Major Expansion by 2034, According to DelveInsight | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic Inc

03-20-2025 02:28 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Achondroplasia Market on Track for Major Expansion by 2034,

The Key Achondroplasia Companies in the marklet include - BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others.

DelveInsight's "Achondroplasia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Forecast [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Achondroplasia Market Report:

*
The Achondroplasia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In September 2024, BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic disorders, announced today that the FDA has granted Breakthrough Therapy Designation to oral infigratinib, which is being developed for pediatric achondroplasia. This designation aims to accelerate the development and regulatory review of drugs in the U.S. that meet strict criteria. To qualify, a drug must show initial clinical evidence of potentially significant improvement on clinically meaningful endpoints compared to existing treatments.

*
In the United States, achondroplasia impacts a slightly higher percentage of females (51.2%) compared to males (48.8%). This slight difference may be attributed to genetic or biological factors that contribute to its somewhat greater prevalence in females.

*
In 2023, the total number of diagnosed prevalent cases of achondroplasia in Japan and the US was approximately 18,000, with expectations for this number to increase in the coming years.

*
In 2023, Japan had around 3,000 diagnosed prevalent cases of achondroplasia.

*
The epidemiology model categorizes age-specific cases into nine groups: 0-4, 5-10, 11-15, 16-20, 21-30, 31-40, 41-50, 51-60, and over 60. DelveInsight's estimates indicate that the 5-10 age group was the most affected in the US, with around 4,000 cases reported in 2023.

*
Achondroplasia is estimated to occur in 1 out of every 15,000 to 40,000 live births, making it one of the most prevalent types of skeletal dysplasia.

*
Key Achondroplasia Companies: BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others

*
Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others

*
The Achondroplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Achondroplasia pipeline products will significantly revolutionize the Achondroplasia market dynamics.

Achondroplasia Overview

Achondroplasia is a genetic disorder and the most common form of dwarfism, characterized by abnormal bone growth that results in short stature with disproportionately short arms and legs, a larger head, and distinctive facial features. It is caused by mutations in the *FGFR3* gene, which affects cartilage formation and bone growth. This condition is typically inherited in an autosomal dominant pattern, meaning that only one copy of the altered gene is sufficient to cause the disorder. While people with achondroplasia often have normal intelligence and lifespan, they may experience certain health challenges such as spinal stenosis, ear infections, and respiratory issues.

Get a Free sample for the Achondroplasia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/fabry-disease-market [https://www.delveinsight.com/report-store/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Achondroplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Achondroplasia Epidemiology Segmentation:

The Achondroplasia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Achondroplasia

*
Prevalent Cases of Achondroplasia by severity

*
Gender-specific Prevalence of Achondroplasia

*
Diagnosed Cases of Episodic and Chronic Achondroplasia

Download the report to understand which factors are driving Achondroplasia epidemiology trends @ Achondroplasia Epidemiology Forecast [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Achondroplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Achondroplasia market or expected to get launched during the study period. The analysis covers Achondroplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Achondroplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Achondroplasia Therapies and Key Companies

*
VOXZOGO (vosoritide): BioMarin Pharmaceuticals

*
Infigratinib: BridgeBio/ QED Therapeutics

*
RBM-007: Ribomic Inc

*
Sanofi: SAR-442501

*
Recombinant human growth hormone: Changchun GeneScience Pharma

*
Infigratinib: QED Therapeutics, Inc.

*
TransCon CNP: Ascendis Pharma A/S

*
Infigratinib: QED Therapeutics, Inc

*
vosoritide: BioMarin Pharmaceuticals

*
BMN 111: BioMarin Pharmaceutical

Discover more about therapies set to grab major Achondroplasia market share @ Achondroplasia Treatment Landscape [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Achondroplasia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Achondroplasia Companies: BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others

*
Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others

*
Achondroplasia Therapeutic Assessment: Achondroplasia current marketed and Achondroplasia emerging therapies

*
Achondroplasia Market Dynamics: Achondroplasia market drivers and Achondroplasia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Achondroplasia Unmet Needs, KOL's views, Analyst's views, Achondroplasia Market Access and Reimbursement

To know more about Achondroplasia companies working in the treatment market, visit @ Achondroplasia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Achondroplasia Market Report Introduction

2. Executive Summary for Achondroplasia

3. SWOT analysis of Achondroplasia

4. Achondroplasia Patient Share (%) Overview at a Glance

5. Achondroplasia Market Overview at a Glance

6. Achondroplasia Disease Background and Overview

7. Achondroplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Achondroplasia

9. Achondroplasia Current Treatment and Medical Practices

10. Achondroplasia Unmet Needs

11. Achondroplasia Emerging Therapies

12. Achondroplasia Market Outlook

13. Country-Wise Achondroplasia Market Analysis (2020-2034)

14. Achondroplasia Market Access and Reimbursement of Therapies

15. Achondroplasia Market Drivers

16. Achondroplasia Market Barriers

17. Achondroplasia Appendix

18. Achondroplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=achondroplasia-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-sanofi-changchun-genescience-pharma-qed-therapeutics-inc-bridgebio-qed-therapeutics-ribomic-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Achondroplasia Market on Track for Major Expansion by 2034, According to DelveInsight | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic Inc here

News-ID: 3927386 • Views:

More Releases from ABNewswire

Vinod Shobha Narayan Patil (VSNP) Urges Constitutional Clarity in Maratha Reservation Policy
Vinod Shobha Narayan Patil (VSNP) Urges Constitutional Clarity in Maratha Reserv …
Vinod Shobha Narayan Patil (VSNP), also known as Vinod SN Patil, has urged a constitutional review of Maharashtra's Maratha reservation policy, calling for lasting reform over temporary fixes. As the original petitioner in PIL No. 140 of 2014, Vinod Patil continues to advocate lawful, equitable solutions for the Maratha community. Image: https://www.abnewswire.com/upload/2025/10/04ad20ebc0348b3d057f9470ef2d75a3.JPG Chhatrapati Sambhajinagar, Maharashtra - Oct 8, 2025 - Social reformer and community advocate Vinod Shobha Narayan Patil (VSNP), widely known
Vinod Patil: Strengthening Communities Through Education and Opportunity for Youth Empowerment and Social Development in Maharashtra
Vinod Patil: Strengthening Communities Through Education and Opportunity for You …
Vinod Shobha Narayan Patil, also known as Vinod SN Patil, is a Maharashtra-based reformer and entrepreneur focused on youth empowerment, education, and rural growth. As Director of Prayog Farmer Producer Company and Partner at Narayan Seth Construction, he blends business with social change, promoting opportunity, ethical leadership, and sustainable community development. Image: https://www.abnewswire.com/upload/2025/10/5eb0f566b4d7a80e9bae5b795bf86ca8.PNG Mumbai, Maharashtra, INDIA - October 8, 2025 - Vinod SN Patil, also known as Vinod Shobha Narayan Patil (VSNP)
Smart Water, Smart Savings: How Orlando Homeowners Can Cut Costs and Conserve Water by Maintaining Their Irrigation Systems
Smart Water, Smart Savings: How Orlando Homeowners Can Cut Costs and Conserve Wa …
Here are some easy tips on saving water when irrigating your landscaping in Orlando Florida. Orlando, FL - In Central Florida, where sunshine and lush greenery define the landscape, sprinkler repair [https://sprinkler-repair-orlando.com/] can be a challenge. As water rates rise and drought concerns persist, Orlando homeowners are finding that one of the best ways to save water - and money - is through proper irrigation system maintenance. According to the St. Johns
Verify550 Launches Integration with HighLevel for Accurate Email Verification and Deliverability
Verify550 Launches Integration with HighLevel for Accurate Email Verification an …
Bend, OR - Verify550, a global leader in email verification and deliverability technology, today announced its new integration with [https://verify550.com/integrations/gohighlevel/]HighLevel [https://verify550.com/integrations/gohighlevel/], the all-in-one marketing and CRM platform trusted by agencies, entrepreneurs, and digital marketers worldwide. The integration enables HighLevel users to automatically validate and clean email addresses in real time within their funnels, forms, and workflows. By detecting invalid, disposable, or high-risk addresses before campaigns deploy, businesses can protect sender reputation,

All 5 Releases


More Releases for Achondroplasia

Achondroplasia Market Predicted to See Upsurge Through 2034, Highlights DelveIns …
DelveInsight's "Achondroplasia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Forecast https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Achondroplasia Market
Achondroplasia Market Industry Trends and Forecast to 2029
This Achondroplasia Market report has been prepared by considering several fragments of the present and upcoming market scenario. The market insights gained through this market research analysis report facilitates more clear understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. It consists of most-detailed market segmentation, thorough analysis of major market players, trends in consumer and supply chain
Achondroplasia Treatment Market Size, Share, Industry, Forecast to 2030
The Achondroplasia Treatment Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Achondroplasia Treatment market. This report explores all the key factors affecting the growth of the global Achondroplasia Treatment market, including
Achondroplasia Treatment Market to witness Great Growth in Forecast to 2030
The professional report on The Achondroplasia Treatment Market research provides valuable insights on business size, ongoing trends, drivers, potential risks, outcomes, and significant segments. Additionally, the Industry Report presents precise assumptions to forecast future market growth. Drawing from industry experts, the report's findings offer actionable measures that help readers develop effective strategies for the Achondroplasia Treatment market's future growth. Furthermore, the research provides a comprehensive view of present market needs
Achondroplasia Market: Pipeline Review, H2 2022
HTF Market Intelligence released a new research report of 60 pages on title 'Achondroplasia - Pipeline Review, H2 2022' with detailed analysis, forecast and strategies. The market Study is segmented by key a region that is accelerating the marketization. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources. This section also provides the scope of different
Achondroplasia (Musculoskeletal) Market Competitive Research And Global Outlook …
The Achondroplasia (Musculoskeletal) Market report offers an in-depth assessment of market dynamics, the competitive landscape, segments, and regions in order to help readers to become familiar with the Achondroplasia (Musculoskeletal) market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies for gaining successful in the Achondroplasia (Musculoskeletal) market. Importantly, it allows players to gain deep insights into